Danhof M, Breimer D D
Br J Clin Pharmacol. 1979 Dec;8(6):529-37. doi: 10.1111/j.1365-2125.1979.tb01040.x.
The plasma elimination rate of antipyrine, as measured by the salivary concentration decay, and the urinary excretion of antipyrine and its primary metabolites 4-hydroxy-antipyrine, norantipyrine, 3-hydroxymethyl-antipyrine and 3-carboxy-antipyrine was studied in five healthy volunteers, who received 250, 500 and 1000 mg antipyrine orally in a cross-over design. The mean antipyrine half-life and metabolic clearance were 11.5 ± 2.5 h (range 10.2-16.9 h) and 3.4 ± 0.9 l/h (range 1.7-4.2 l/h) respectively after 500 mg. These values were not significantly different after 250 or 1000 mg ( > 0.1; paired -test). In 52 h urine 3.3 ± 1.2% of the dose of 500 mg antipyrine was excreted unchanged as antipyrine, 28.5 ± 2.2% as 4-hydroxy-antipyrine, 16.5 ± 6.0% as norantipyrine, 35.1 ± 7.2% as 3-hydroxymethyl-antipyrine and 3.3 ± 0.8% as 3-carboxy-antipyrine. The values obtained at the other dose levels were not significantly different ( > 0.1; paired -test). At all dose levels 4-hydroxy-antipyrine and norantipyrine were excreted in urine entirely as glucuronides. After 500 mg antipyrine, 3-hydroxymethyl-antipyrine was excreted as glucuronide to the extent of 58 ± 9% of the total excreted amount. This percentage was not significantly different at the other dose levels. 3-Carboxy-antipyrine was excreted in the free form at all three dose levels. From 12 h of drug intake onwards, the urinary excretion rate curves of antipyrine and all its metabolites declined mono-exponentially with about the same half-life as the parent compound in saliva. The half-lives calculated from the excretion rate curves of 4-hydroxy-antipyrine, norantipyrine and 3-hydroxymethyl-antipyrine correlated significantly with the half-life of antipyrine in plasma. At all dose levels a relative delay in urinary excretion of 3-hydroxymethyl-antipyrine was observed compared to the urinary excretion of antipyrine and the other metabolites. The ratios of the cumulative amounts of metabolites excreted in 24 h, were essentially the same as those measured in the 52 h samples.
通过唾液浓度衰减测定了安替比林的血浆消除率,并研究了安替比林及其主要代谢产物4-羟基安替比林、去甲安替比林、3-羟甲基安替比林和3-羧基安替比林在5名健康志愿者中的尿排泄情况。这些志愿者采用交叉设计口服250、500和1000 mg安替比林。服用500 mg后,安替比林的平均半衰期和代谢清除率分别为11.5±2.5小时(范围10.2 - 16.9小时)和3.4±0.9升/小时(范围1.7 - 4.2升/小时)。服用250 mg或1000 mg后,这些值无显著差异(>0.1;配对t检验)。在52小时尿液中,500 mg安替比林剂量中3.3±1.2%以安替比林原形排出,28.5±2.2%以4-羟基安替比林排出,16.5±6.0%以去甲安替比林排出,35.1±7.2%以3-羟甲基安替比林排出,3.3±0.8%以3-羧基安替比林排出。在其他剂量水平获得的值无显著差异(>0.1;配对t检验)。在所有剂量水平,4-羟基安替比林和去甲安替比林在尿液中完全以葡糖醛酸苷形式排出。服用500 mg安替比林后,3-羟甲基安替比林以葡糖醛酸苷形式排出的量占总排出量的58±9%。在其他剂量水平,该百分比无显著差异。3-羧基安替比林在所有三个剂量水平均以游离形式排出。从服药12小时起,安替比林及其所有代谢产物的尿排泄率曲线呈单指数下降,半衰期与唾液中母体化合物的半衰期大致相同。由4-羟基安替比林、去甲安替比林和3-羟甲基安替比林的排泄率曲线计算出的半衰期与血浆中安替比林的半衰期显著相关。与安替比林和其他代谢产物的尿排泄相比,在所有剂量水平均观察到3-羟甲基安替比林的尿排泄存在相对延迟。24小时内排泄的代谢产物累积量之比与52小时样本中测得的基本相同。